Literature DB >> 18830558

Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes.

Yukio Ikeda1, Mari Inoue, Tadashi Suehiro, Kaoru Arii, Yoshitaka Kumon, Kozo Hashimoto.   

Abstract

Human serum paraoxonase (PON1) is associated with HDL and inhibits oxidative modification of LDL. PON1 enzymatic activity has been shown to decrease in diabetic patients; however, the effect of PON1 status on long-term outcome has not been reported. In this study, we examined the association between baseline PON1 status and the development of cardiovascular disease (CVD) during 10 years of follow-up in 88 type 2 diabetic patients whose enzymatic activities, concentrations, and genetic polymorphisms of PON1 had been determined. A total of 20 CVD events were recorded during the follow-up period. Using Kaplan-Meier survival curves, we found a significantly increased incidence of CVD in patients with a lower concentration or paraoxonase activity of PON1 than each median value (log-rank 7.460; P < 0.01, and log-rank 4.187; P < 0.05, respectively). By Cox regression analysis, both concentration and paraoxonase activity were significantly associated with the development of CVD, even after correction for gender, age, and preexisting CVD (P < 0.05). Low concentration and enzymatic activity of PON1 may be an independent predictor of cardiovascular events in diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18830558     DOI: 10.1007/s00592-008-0066-3

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  15 in total

1.  The effect of grape seed extracts on serum paraoxonase activities in streptozotocin-induced diabetic rats.

Authors:  Aysel Kiyici; Nilsel Okudan; Hakki Gökbel; Muaz Belviranli
Journal:  J Med Food       Date:  2010-06       Impact factor: 2.786

Review 2.  Cholesteryl Ester Transfer Protein Inhibitors - Future Soon to be REVEALed.

Authors:  Christopher Huggins; Nicoletta Charolidi; Gillian W Cockerill
Journal:  Eur Cardiol       Date:  2015-07

Review 3.  The genetics of vascular complications in diabetes mellitus.

Authors:  Dan Farbstein; Andrew P Levy
Journal:  Cardiol Clin       Date:  2010-08       Impact factor: 2.213

Review 4.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

Review 5.  Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles.

Authors:  Mike Mackness; Bharti Mackness
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

6.  Effects of vitamin A, C and E, or omega-3 fatty acid supplementation on the level of paraoxonase and arylesterase activity in streptozotocin-induced diabetic rats: an investigation of activities in plasma, and heart and liver homogenates.

Authors:  Mahnaz Zarei; Shima Fakher; Seyed Mohammad Bagher Tabei; Mohammad Hassan Javanbakht; Hoda Derakhshanian; Payam Farahbakhsh-Farsi; Mohammad Reza Sadeghi; Ebrahim Mostafavi; Mahmoud Djalali
Journal:  Singapore Med J       Date:  2016-03       Impact factor: 1.858

7.  High density lipoproteins and type 2 diabetes: Emerging concepts in their relationship.

Authors:  Michael S Kostapanos; Moses S Elisaf
Journal:  World J Exp Med       Date:  2014-02-20

8.  Regulation of hepatic paraoxonase-1 expression.

Authors:  Bianca Fuhrman
Journal:  J Lipids       Date:  2012-04-03

9.  Paraoxonase-1 (PON1) promoter region polymorphisms, serum PON1 status and coronary heart disease.

Authors:  Bharti Mackness; Wajdi Turkie; Mike Mackness
Journal:  Arch Med Sci       Date:  2013-02-10       Impact factor: 3.318

10.  Association of lipids with oxidative stress biomarkers in subclinical hypothyroidism.

Authors:  Adriana Santi; Marta M M F Duarte; Charlene C de Menezes; Vania Lucia Loro
Journal:  Int J Endocrinol       Date:  2012-11-29       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.